ArticleNaunyn-Schmiedeberg's archives of pharmacology2013
Pharmacological profile of β3-adrenoceptor agonists in clinical development for the treatment of overactive bladder syndrome.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 3 syntheses or guidelines pooled it, 86 citations in OpenAlex.
- The impact of pharmacotherapy on sexual function in female patients being treated for idiopathic overactive bladder: a systematic review.BMC women's health · 2024Pooled it
- The Efficacy of Mirabegron in Medical Expulsive Therapy for Ureteral Stones: A Systematic Review and Meta-Analysis.International journal of clinical practice · 2022Pooled it
- Overactive bladder - 18 years - Part II.International braz j urol : official journal of the Brazilian Society of UrologyPooled it
- Efficacy and safety of combination of mirabegron and solifenacin in patients with double-J stent related overactive bladder: a prospective study.Scientific reports · 2022Trial
- Mirabegron in medical expulsive therapy for distal ureteral stones: a prospective, randomized, controlled study.World journal of urology · 2021Trial
- A bibliometric study of the most-cited research articles and reviews in Naunyn-Schmiedeberg's Archives of Pharmacology (1969-2024).Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Inside the Biology of the β3-Adrenoceptor.Biomolecules · 2024Review
- Adrenoceptors: Receptors, Ligands and Their Clinical Uses, Molecular Pharmacology and Assays.Handbook of experimental pharmacology · 2024Review
- Efficacy and safety of pelvic floor magnetic stimulation combined with mirabegron in female patients with refractory overactive bladder: a prospective study.Frontiers in neuroscience · 2024Article
- The βAdvances in pharmacological and pharmaceutical sciences · 2024Review
- Mirabegron, a Selective β3-Adrenergic Receptor Agonist, as a Potential Anti-Obesity Drug.Journal of clinical medicine · 2023Review
- Mirabegron and solifenacin are effective for the management of the increased urinary frequency induced by psychological stress in female mice.Scientific reports · 2022Article
- Pharmacophore-guided Virtual Screening to Identify New βMolecular informatics · 2022Article
- Mirabegron attenuates porcine ureteral contractility via α1-adrenoceptor antagonism.Naunyn-Schmiedeberg's archives of pharmacology · 2022Article
- Decoupling Oxygen Tension From Retinal Vascularization as a New Perspective for Management of Retinopathy of Prematurity. New Opportunities From β-adrenoceptors.Frontiers in pharmacology · 2022Review
- Chemogenetic approaches to identify metabolically important GPCR signaling pathways: Therapeutic implications.Journal of neurochemistry · 2021Review
- β3-Adrenoreceptors as ROS Balancer in Hematopoietic Stem Cell Transplantation.International journal of molecular sciences · 2021Review
- Additive effects of intravenous and intravesical application of vibegron, a βNaunyn-Schmiedeberg's archives of pharmacology · 2020Article
- The Regulator of G Protein Signaling Homologous Domain of G Protein-Coupled Receptor Kinase 2 Mediates Short-Term Desensitization of β3-Adrenergic Receptor.Frontiers in pharmacology · 2020Article
- β-Adrenoceptors as drug targets in melanoma: novel preclinical evidence for a role of βBritish journal of pharmacology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
β(3)-Adrenoceptor agonists are an emerging drug class for the treatment of the overactive bladder syndrome, and clinical proof-of-concept data have been obtained for three representatives of this class, mirabegron, ritobegron, and solabegron. We review here the pharmacological profile of these three drugs and discuss the potential clinical relevance of differences between them. In the absence of direct comparative studies, it appears that all three are strong agonists selective for β(3)- vs. β(1)- and β(2)-adrenoceptors in studies with cloned receptor subtypes. The potency of these agonists may be species-dependent, with all three having high potency in the human detrusor. All three agonists were effective in one or more animal models of bladder dysfunction, which typically involved reductions of micturition frequency. Agonist doses effective for bladder function lowered blood pressure in some cases, but the relevance of this for clinical use is difficult to determine due to species differences in the importance of cardiovascular β(3)-adrenoceptors. While limited effects on other organ systems are expected for β(3)-adrenoceptor agonists, this requires further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.